Global HIV Drugs Market Research And Application to 2019

HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections.

The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection.

This is mainly used to keep the level of the HIV low in the body. The report analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.

Covered in this report:

This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.

Based on the class of drugs, the market is segmented as follows:

•  Multi-class combination products 
•  Nucleoside reverse transcriptase inhibitors
•  Non-nucleoside reverse transcriptase inhibitors
•  Protease inhibitors
•  Fusion inhibitors
•  Entry inhibitors - CCR5 co-receptor antagonist
•  HIV integrase strand transfer inhibitors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios.

To Request Sample Copy:
http://www.radiantinsights.com/research/global-hiv-drugs-market-2015-2019#tabs-4

In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Global HIV Drugs Market has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

•  Americas
•  APAC
•  EMEA

Key vendors

•  Bristol-Myers Squibb
•  Gilead Sciences
•  GlaxoSmithKline
•  Johnson & Johnson
•  Merck

Other prominent vendors

•  AbbVie
•  AstraZeneca
•  Boehringer Ingelheim
•  Cipla
•  Daiichi Sankyo
•  Emcure
•  F. Hoffmann-La Roche
•  Hetero Drugs
•  Mylan
•  Pfizer
•  Shionogi
•  Teva Pharmaceutical Industries

Market driver

•  Inflow of funds
•  For a full, detailed list, view our report

Market challenge

•  Patent expiries
•  For a full, detailed list, view our report

Market trend

•  Increasing public awareness
•  For a full, detailed list, view our report

Key questions answered in this report

•  What will the market size be in 2019 and what will the growth rate be?
•  What are the key market trends?
•  What is driving this market?
•  What are the challenges to market growth?
•  Who are the key vendors in this market space?
•  What are the market opportunities and threats faced by the key vendors?
•  What are the strengths and weaknesses of the key vendors?